The National Health Expenditure has continued to increase, as an aging population seeks more healthcare services. The US healthcare industry, though, has faced challenging conditions arising from the pandemic that continued in 2024, including high inflation rates, labor shortages, and constrained funding. In this environment, the industry has continued to adapt through performance improvement efforts as well as pursuing growing segments like HST and specialty pharmacy. McKinsey expects the EBITDA recovery to continue in most segments through accelerated performance improvement efforts, including greater application of technology, as well as growth in areas such as the Medicare and Medicaid duals population, software, data, analytics, and specialty pharmacy.
Read the full article: McKinsey: What to Expect in US Healthcare in 2025 and Beyond //
Source: https://www.mckinsey.com/industries/healthcare/our-insights/what-to-expect-in-us-healthcare-in-2025-and-beyond